Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

被引：0

作者：

Voorhees, Peter M. ^{[1
]}

Kaufman, Jonathan L. ^{[2
]}

Laubach, Jacob P. ^{[3
]}

Sborov, Douglas W. ^{[4
]}

Reeves, Brandi ^{[5
]}

Rodriguez, Cesar ^{[6
]}

Chari, Ajai ^{[7
]}

Silbermann, Rebecca W. ^{[8
]}

Costa, Luciano J. ^{[9
]}

Anderson, Larry D. ^{[10
]}

Nathwani, Nitya ^{[11
]}

Shah, Nina D. ^{[12
]}

Efebera, Yvonne A. ^{[13
]}

Costello, Caitlin L. ^{[14
]}

Jakubowiak, Andrzej ^{[15
]}

Wildes, Tanya M. ^{[16
]}

Orlowski, Robert Z. ^{[17
]}

Shain, Kenneth H. ^{[18
]}

Cowan, Andrew J. ^{[19
]}

Murphy, Sean ^{[20
]}

Lutska, Yana ^{[20
]}

Pei, Huiling ^{[21
]}

Ukropec, Jon ^{[22
]}

Vermeulen, Jessica ^{[23
]}

de Boer, Carla ^{[23
]}

Hoehn, Daniela ^{[20
]}

Lin, Thomas S. ^{[20
]}

Richardson, Paul G. ^{[3
]}

机构：

[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT USA

[5] Univ N Carolina, Chapel Hill, NC 27515 USA

[6] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA

[7] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA

[8] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[9] Univ Alabama Birmingham, Birmingham, AL USA

[10] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Hematol Oncol, Dallas, TX USA

[11] City Hope Comprehens Canc Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA

[12] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[13] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[14] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[15] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[16] Washington Univ, Div Oncol, Sect Med Oncol, St Louis, MO USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[18] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, St Petersburg, FL USA

[19] Univ Washington, Div Med Oncol, Seattle, WA USA

[20] Janssen Sci Affairs LLC, Horsham, PA USA

[21] Janssen Res & Dev LLC, Titusville, NJ USA

[22] Janssen Global Med Affairs, Horsham, PA USA

[23] Janssen Res & Dev LLC, Leiden, Netherlands

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

691

引用

页数：7

共 50 条

[41] Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Shah, Jatin J.
Feng, Lei
Manasanch, Elisabet E.
Weber, Donna M.
Thomas, Sheeba K.
Turturro, Francesco
Alexanian, Raymond
Shah, Nina
Popat, Uday R.
Nieto, Yago
Bashir, Qaiser
Qazilbash, Muzaffar H.
Champlin, Richard E.
Orlowski, Robert Z.
BLOOD, 2014, 124 (21)
[42] Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Shah, Jatin J.
Feng, Lei
Manasanch, Elisabet E.
Weber, Donna
Thomas, Sheeba K.
Turturro, Francesco
Shah, Nina
Popat, Uday R.
Nieto, Yago
Bashir, Qaiser
Munoz, Silvia C.
Landry, Ashley
Mendoza, Kathleen
Champlin, Richard E.
Qazilbash, Muzaffar H.
Orlowski, Robert Z.
BLOOD, 2015, 126 (23)
[43] Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China
Fu, Chengcheng
Wang, Jing
Yan, Lingzhi
Jin, Song
Shang, Jingjing
Shi, Xiaolan
Yao, Weiqin
Yan, Zhi
Wu, De-Pei
BLOOD, 2023, 142
[44] Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
Chari, Ajai
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Silbermann, Rebecca
Costa, Luciano J.
Anderson Jr, Larry D.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Voorhees, Peter M.
Usmani, Saad Z.
Richardson, Paul G.
BLOOD CANCER JOURNAL, 2024, 14 (01):
[45] Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
Sonneveld, Pieter
Moreau, Philippe
Dimopoulos, Meletios A.
Quach, Hang
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
Nijhof, Inger S.
van de Donk, Niels W. C. J.
Katodritou, Eirini
Schjesvold, Fredrik
Sureda Balari, Anna
Rosinol, Laura
Delforge, Michel
Roeloffzen, Wilfried
Driessen, Christoph
Vangsted, Annette
Einsele, Hermann
Spencer, Andrew
Hajek, Roman
Jurczyszyn, Artur
Lonergan, Sarah
Liu, Yanfang
Wang, Jianping
Vieyra, Diego
van Brummelen, Emilie M. J.
Vanquickelberghe, Veronique
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Blade, Joan
Boccadoro, Mario
Rodriguez-Otero, Paula
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S550 - S551
[46] Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
Wang, Yin-Che
Lin, Cheng-Hsien
Su, Yu-Chen
Teng, Chieh-Lin Jerry
HEMATOLOGY, 2025, 30 (01)
[47] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: a quadruplet intensified treatment for transplant eligible newly diagnosed Multiple Myeloma (TE NDMM) patients final results
Crusoe, Edvan
Santos, Juliana
Leal, JOanna
Santos, Herbert
Santos, Allan
Almeida, Alessandro
Santos, Mariane
Lucas, Larissa
Queiroz, Sarah
Fonseca, Cleverson
Adorno, Elisangela
Vieira, Lucas
Hungria, Vania
Salvino, Marco
Arruda, Maria da Gloria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S130 - S130
[48] Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma
Rosinol, Laura
Hebraud, Benjamin
Oriol, Albert
Colin, Anne-Laurene
Tamayo, Rafael Rios
Hulin, Cyrille
Blanchard, Maria Jesus
Caillot, Denis
Balari, Anna Sureda
Hernandez, Miguel T.
Arnulf, Bertrand
Mateos, Maria-Victoria
Macro, Margaret
San-Miguel, Jesus
Belhadj, Karim
Lahuerta, Juan-Jose
Garelik, M. Brigid
Blade, Joan
Moreau, Philippe
Attal, Michel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E1 - E2
[49] Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Joseph, Nisha S.
Kaufman, Jonathan L.
Gupta, Vilas A.
Hofmeister, Craig C.
Dhodapkar, Madhav V.
Boise, Lawrence H.
DiCamillo, Sara M.
Roberts, Danielle
Nooka, Ajay K.
Lonial, Sagar
BLOOD CANCER JOURNAL, 2024, 14 (01):
[50] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTD) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-Risk Patients in Cassiopeia
Sonneveld, Pieter
Attal, Michel
Perrot, Aurore
Hulin, Cyrille
Caillot, Denis
Facon, Thierry
Leleu, Xavier
Belhadj, Karim
Karlin, Lionel
Benboubker, Lotfi
Levin, Mark-David
Minnema, Monique C.
Westerman, Matthijs
Delforge, Michel
Zweegman, Sonja
Pei, Lixia
de Boer, Carla
Vanquickelberghe, Veronique
Kampfenkel, Tobias
Moreau, Philippe
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 124 - 126

← 1 2 3 4 5 →